INSPECT Certification Requirement Law:
ATTENTION – Effective July 1, 2019, pursuant to IC 35-48-3-3.5, a practitioner who is licensed by a board under IC 25-1-9 and applies for registration or reregistration under this chapter must have completed two (2) hours of continuing education during the previous two (2) years addressing the topic of opioid prescribing and opioid abuse.
(c) All continuing education courses required under subsection (b) must be:
(1) approved by the board or the licensing board that regulates the practitioner; or
(2) offered by an approved organization (as defined by IC 25-1-4-0.2).
Important Notice regarding Changes to Indiana Law concerning the Prescribing and Dispensing of Opioids:
ATTENTION - Effective July 1, 2017, pursuant to Senate Enrolled Act 226, new laws concerning the prescribing and dispensing of opioids will go into effect. Please be advised, these changes affect any practitioner who maintains an Indiana controlled substance registration and a federal Drug Enforcement Administration registration as well as any pharmacy or pharmacist dispensing opioid prescriptions. The Medical Licensing Board is currently reviewing the statute should any considerations for the prescribing of opioids be necessary. For more information and a copy of the enrolled act, please visit the Indiana General Assembly website here.
Please note, that neither the Professional Licensing Agency nor its boards, can provide legal guidance regarding these laws. If you require legal assistance, please contact a private attorney.
ATTENTION - Effective July 1, 2016, pursuant to IC 25-26-13-4, ephedrine and pseudoephedrine,
when dispensed via prescription, are each considered a "controlled substance" for the purposes of the INSPECT program. All prescription dispensations of these drugs must be reported to INSPECT. Over-the-counter purchases are not reported to INSPECT and must still be processed through NPLEx.
ATTENTION - Effective July 1, 2016, pursuant to IC 35-48-2-8(c)(3), Butalbital, commonly known as Fioricet, is a Schedule III substance in the State of Indiana. As a result, Schedule III requirements in the Indiana Controlled Substances Act and associated administrative rules in 856 IAC 2 apply to its handling and dispensation.
The Indiana Board of Pharmacy will enforce Schedule III requirements for Butalbital 60 days from the date of this communication. Please note specifically that existing prescriptions will be valid but refills outside of that allowed under Schedule III will be invalid. Further, as a Schedule III substance, an initial inventory is needed and Butalbital must be included in your biennial inventory.
ATTENTION - Effective January 1, 2016, ALL controlled substances dispensed, including zero reports, must be reported within twenty-four (24) hours or by the close of the next business day if the dispenser is closed the day following the dispensing. Additionally, all errant records must be corrected and resubmitted within twenty-four (24) hours (meaning the next business day).